1 Market Overview 1.1 Product Overview and Scope of Targeted Drug VEGF Inhibitors for NSCLC 1.2 Classification of Targeted Drug VEGF Inhibitors for NSCLC by Type 1.2.1 Overview: Global Targeted Drug VEGF Inhibitors for NSCLC Market Size by Type: 2020 Versus 2021 Versus 2026 1.2.2 Global Targeted Drug VEGF Inhibitors for NSCLC Revenue Market Share by Type in 2020 1.2.3 Bevacizumab 1.2.4 Other 1.3 Global Targeted Drug VEGF Inhibitors for NSCLC Market by Application 1.3.1 Overview: Global Targeted Drug VEGF Inhibitors for NSCLC Market Size by Application: 2020 Versus 2021 Versus 2026 1.3.2 Squamous Cell Carcinoma of NSCLC 1.3.3 Adenocarcinoma of NSCLC 1.3.4 Large Cell Carcinoma of NSCLC 1.4 Global Targeted Drug VEGF Inhibitors for NSCLC Market Size & Forecast 1.5 Global Targeted Drug VEGF Inhibitors for NSCLC Market Size and Forecast by Region 1.5.1 Global Targeted Drug VEGF Inhibitors for NSCLC Market Size by Region: 2016 VS 2021 VS 2026 1.5.2 Global Targeted Drug VEGF Inhibitors for NSCLC Market Size by Region, (2016-2021) 1.5.3 North America Targeted Drug VEGF Inhibitors for NSCLC Market Size and Prospect (2016-2026) 1.5.4 Europe Targeted Drug VEGF Inhibitors for NSCLC Market Size and Prospect (2016-2026) 1.5.5 Asia-Pacific Targeted Drug VEGF Inhibitors for NSCLC Market Size and Prospect (2016-2026) 1.5.6 South America Targeted Drug VEGF Inhibitors for NSCLC Market Size and Prospect (2016-2026) 1.5.7 Middle East and Africa Targeted Drug VEGF Inhibitors for NSCLC Market Size and Prospect (2016-2026) 1.6 Market Drivers, Restraints and Trends 1.6.1 Targeted Drug VEGF Inhibitors for NSCLC Market Drivers 1.6.2 Targeted Drug VEGF Inhibitors for NSCLC Market Restraints 1.6.3 Targeted Drug VEGF Inhibitors for NSCLC Trends Analysis 2 Company Profiles 2.1 Roche 2.1.1 Roche Details 2.1.2 Roche Major Business 2.1.3 Roche Targeted Drug VEGF Inhibitors for NSCLC Product and Solutions 2.1.4 Roche Targeted Drug VEGF Inhibitors for NSCLC Revenue, Gross Margin and Market Share (2019-2021) 2.1.5 Roche Recent Developments and Future Plans 2.2 Pfizer 2.2.1 Pfizer Details 2.2.2 Pfizer Major Business 2.2.3 Pfizer Targeted Drug VEGF Inhibitors for NSCLC Product and Solutions 2.2.4 Pfizer Targeted Drug VEGF Inhibitors for NSCLC Revenue, Gross Margin and Market Share (2019-2021) 2.2.5 Pfizer Recent Developments and Future Plans 2.3 Allergan 2.3.1 Allergan Details 2.3.2 Allergan Major Business 2.3.3 Allergan Targeted Drug VEGF Inhibitors for NSCLC Product and Solutions 2.3.4 Allergan Targeted Drug VEGF Inhibitors for NSCLC Revenue, Gross Margin and Market Share (2019-2021) 2.3.5 Allergan Recent Developments and Future Plans 2.4 Amgen 2.4.1 Amgen Details 2.4.2 Amgen Major Business 2.4.3 Amgen Targeted Drug VEGF Inhibitors for NSCLC Product and Solutions 2.4.4 Amgen Targeted Drug VEGF Inhibitors for NSCLC Revenue, Gross Margin and Market Share (2019-2021) 2.4.5 Amgen Recent Developments and Future Plans 2.5 Biocon 2.5.1 Biocon Details 2.5.2 Biocon Major Business 2.5.3 Biocon Targeted Drug VEGF Inhibitors for NSCLC Product and Solutions 2.5.4 Biocon Targeted Drug VEGF Inhibitors for NSCLC Revenue, Gross Margin and Market Share (2019-2021) 2.5.5 Biocon Recent Developments and Future Plans 2.6 Reliance Lifesciences 2.6.1 Reliance Lifesciences Details 2.6.2 Reliance Lifesciences Major Business 2.6.3 Reliance Lifesciences Targeted Drug VEGF Inhibitors for NSCLC Product and Solutions 2.6.4 Reliance Lifesciences Targeted Drug VEGF Inhibitors for NSCLC Revenue, Gross Margin and Market Share (2019-2021) 2.6.5 Reliance Lifesciences Recent Developments and Future Plans 2.7 Beaconpharma 2.7.1 Beaconpharma Details 2.7.2 Beaconpharma Major Business 2.7.3 Beaconpharma Targeted Drug VEGF Inhibitors for NSCLC Product and Solutions 2.7.4 Beaconpharma Targeted Drug VEGF Inhibitors for NSCLC Revenue, Gross Margin and Market Share (2019-2021) 2.7.5 Beaconpharma Recent Developments and Future Plans 2.8 Celgene Corporation 2.8.1 Celgene Corporation Details 2.8.2 Celgene Corporation Major Business 2.8.3 Celgene Corporation Targeted Drug VEGF Inhibitors for NSCLC Product and Solutions 2.8.4 Celgene Corporation Targeted Drug VEGF Inhibitors for NSCLC Revenue, Gross Margin and Market Share (2019-2021) 2.8.5 Celgene Corporation Recent Developments and Future Plans 2.9 Fujifilm Kyowa Kirin Biologics 2.9.1 Fujifilm Kyowa Kirin Biologics Details 2.9.2 Fujifilm Kyowa Kirin Biologics Major Business 2.9.3 Fujifilm Kyowa Kirin Biologics Targeted Drug VEGF Inhibitors for NSCLC Product and Solutions 2.9.4 Fujifilm Kyowa Kirin Biologics Targeted Drug VEGF Inhibitors for NSCLC Revenue, Gross Margin and Market Share (2019-2021) 2.9.5 Fujifilm Kyowa Kirin Biologics Recent Developments and Future Plans 2.10 Hetero Drugs 2.10.1 Hetero Drugs Details 2.10.2 Hetero Drugs Major Business 2.10.3 Hetero Drugs Targeted Drug VEGF Inhibitors for NSCLC Product and Solutions 2.10.4 Hetero Drugs Targeted Drug VEGF Inhibitors for NSCLC Revenue, Gross Margin and Market Share (2019-2021) 2.10.5 Hetero Drugs Recent Developments and Future Plans 3 Market Competition, by Players 3.1 Global Targeted Drug VEGF Inhibitors for NSCLC Revenue and Share by Players (2019-2021) 3.2 Market Concentration Rate 3.2.1 Top 3 Targeted Drug VEGF Inhibitors for NSCLC Players Market Share 3.2.2 Top 10 Targeted Drug VEGF Inhibitors for NSCLC Players Market Share 3.2.3 Market Competition Trend 3.3 Targeted Drug VEGF Inhibitors for NSCLC Players Head Office, Products and Services Provided 3.4 Mergers & Acquisitions 3.5 New Entrants and Expansion Plans 4 Market Size Segment by Type 4.1 Global Targeted Drug VEGF Inhibitors for NSCLC Revenue and Market Share by Type (2016-2021) 4.2 Global Targeted Drug VEGF Inhibitors for NSCLC Market Forecast by Type (2021-2026) 5 Market Size Segment by Application 5.1 Global Targeted Drug VEGF Inhibitors for NSCLC Revenue Market Share by Application (2016-2021) 5.2 Targeted Drug VEGF Inhibitors for NSCLC Market Forecast by Application (2021-2026) 6 North America by Country, by Type, and by Application 6.1 North America Targeted Drug VEGF Inhibitors for NSCLC Revenue by Type (2016-2026) 6.2 North America Targeted Drug VEGF Inhibitors for NSCLC Revenue by Application (2016-2026) 6.3 North America Targeted Drug VEGF Inhibitors for NSCLC Market Size by Country 6.3.1 North America Targeted Drug VEGF Inhibitors for NSCLC Revenue by Country (2016-2026) 6.3.2 United States Targeted Drug VEGF Inhibitors for NSCLC Market Size and Forecast (2016-2026) 6.3.3 Canada Targeted Drug VEGF Inhibitors for NSCLC Market Size and Forecast (2016-2026) 6.3.4 Mexico Targeted Drug VEGF Inhibitors for NSCLC Market Size and Forecast (2016-2026) 7 Europe by Country, by Type, and by Application 7.1 Europe Targeted Drug VEGF Inhibitors for NSCLC Revenue by Type (2016-2026) 7.2 Europe Targeted Drug VEGF Inhibitors for NSCLC Revenue by Application (2016-2026) 7.3 Europe Targeted Drug VEGF Inhibitors for NSCLC Market Size by Country 7.3.1 Europe Targeted Drug VEGF Inhibitors for NSCLC Revenue by Country (2016-2026) 7.3.2 Germany Targeted Drug VEGF Inhibitors for NSCLC Market Size and Forecast (2016-2026) 7.3.3 France Targeted Drug VEGF Inhibitors for NSCLC Market Size and Forecast (2016-2026) 7.3.4 United Kingdom Targeted Drug VEGF Inhibitors for NSCLC Market Size and Forecast (2016-2026) 7.3.5 Russia Targeted Drug VEGF Inhibitors for NSCLC Market Size and Forecast (2016-2026) 7.3.6 Italy Targeted Drug VEGF Inhibitors for NSCLC Market Size and Forecast (2016-2026) 8 Asia-Pacific by Region, by Type, and by Application 8.1 Asia-Pacific Targeted Drug VEGF Inhibitors for NSCLC Revenue by Type (2016-2026) 8.2 Asia-Pacific Targeted Drug VEGF Inhibitors for NSCLC Revenue by Application (2016-2026) 8.3 Asia-Pacific Targeted Drug VEGF Inhibitors for NSCLC Market Size by Region 8.3.1 Asia-Pacific Targeted Drug VEGF Inhibitors for NSCLC Revenue by Region (2016-2026) 8.3.2 China Targeted Drug VEGF Inhibitors for NSCLC Market Size and Forecast (2016-2026) 8.3.3 Japan Targeted Drug VEGF Inhibitors for NSCLC Market Size and Forecast (2016-2026) 8.3.4 South Korea Targeted Drug VEGF Inhibitors for NSCLC Market Size and Forecast (2016-2026) 8.3.5 India Targeted Drug VEGF Inhibitors for NSCLC Market Size and Forecast (2016-2026) 8.3.6 Southeast Asia Targeted Drug VEGF Inhibitors for NSCLC Market Size and Forecast (2016-2026) 8.3.7 Australia Targeted Drug VEGF Inhibitors for NSCLC Market Size and Forecast (2016-2026) 9 South America by Country, by Type, and by Application 9.1 South America Targeted Drug VEGF Inhibitors for NSCLC Revenue by Type (2016-2026) 9.2 South America Targeted Drug VEGF Inhibitors for NSCLC Revenue by Application (2016-2026) 9.3 South America Targeted Drug VEGF Inhibitors for NSCLC Market Size by Country 9.3.1 South America Targeted Drug VEGF Inhibitors for NSCLC Revenue by Country (2016-2026) 9.3.2 Brazil Targeted Drug VEGF Inhibitors for NSCLC Market Size and Forecast (2016-2026) 9.3.3 Argentina Targeted Drug VEGF Inhibitors for NSCLC Market Size and Forecast (2016-2026) 10 Middle East & Africa by Country, by Type, and by Application 10.1 Middle East & Africa Targeted Drug VEGF Inhibitors for NSCLC Revenue by Type (2016-2026) 10.2 Middle East & Africa Targeted Drug VEGF Inhibitors for NSCLC Revenue by Application (2016-2026) 10.3 Middle East & Africa Targeted Drug VEGF Inhibitors for NSCLC Market Size by Country 10.3.1 Middle East & Africa Targeted Drug VEGF Inhibitors for NSCLC Revenue by Country (2016-2026) 10.3.2 Turkey Targeted Drug VEGF Inhibitors for NSCLC Market Size and Forecast (2016-2026) 10.3.3 Saudi Arabia Targeted Drug VEGF Inhibitors for NSCLC Market Size and Forecast (2016-2026) 10.3.4 UAE Targeted Drug VEGF Inhibitors for NSCLC Market Size and Forecast (2016-2026) 11 Research Findings and Conclusion 12 Appendix 12.1 Methodology 12.2 Research Process and Data Source 12.3 Disclaimer

List of Tables Table 1. Global Targeted Drug VEGF Inhibitors for NSCLC Revenue by Type, (USD Million), 2020 VS 2021 VS 2026 Table 2. Global Targeted Drug VEGF Inhibitors for NSCLC Revenue by Application, (USD Million), 2020 VS 2021 VS 2026 Table 3. Global Market Targeted Drug VEGF Inhibitors for NSCLC Revenue (Million USD) Comparison by Region (2016 VS 2021 VS 2026) Table 4. Global Targeted Drug VEGF Inhibitors for NSCLC Revenue (USD Million) by Region (2016-2021) Table 5. Global Targeted Drug VEGF Inhibitors for NSCLC Revenue Market Share by Region (2021-2026) Table 6. Roche Corporate Information, Head Office, and Major Competitors Table 7. Roche Major Business Table 8. Roche Targeted Drug VEGF Inhibitors for NSCLC Product and Solutions Table 9. Roche Targeted Drug VEGF Inhibitors for NSCLC Revenue (USD Million), Gross Margin and Market Share (2019-2021) Table 10. Pfizer Corporate Information, Head Office, and Major Competitors Table 11. Pfizer Major Business Table 12. Pfizer Targeted Drug VEGF Inhibitors for NSCLC Product and Solutions Table 13. Pfizer Targeted Drug VEGF Inhibitors for NSCLC Revenue (USD Million), Gross Margin and Market Share (2019-2021) Table 14. Allergan Corporate Information, Head Office, and Major Competitors Table 15. Allergan Major Business Table 16. Allergan Targeted Drug VEGF Inhibitors for NSCLC Product and Solutions Table 17. Allergan Targeted Drug VEGF Inhibitors for NSCLC Revenue (USD Million), Gross Margin and Market Share (2019-2021) Table 18. Amgen Corporate Information, Head Office, and Major Competitors Table 19. Amgen Major Business Table 20. Amgen Targeted Drug VEGF Inhibitors for NSCLC Product and Solutions Table 21. Amgen Targeted Drug VEGF Inhibitors for NSCLC Revenue (USD Million), Gross Margin and Market Share (2019-2021) Table 22. Biocon Corporate Information, Head Office, and Major Competitors Table 23. Biocon Major Business Table 24. Biocon Targeted Drug VEGF Inhibitors for NSCLC Product and Solutions Table 25. Biocon Targeted Drug VEGF Inhibitors for NSCLC Revenue (USD Million), Gross Margin and Market Share (2019-2021) Table 26. Reliance Lifesciences Corporate Information, Head Office, and Major Competitors Table 27. Reliance Lifesciences Major Business Table 28. Reliance Lifesciences Targeted Drug VEGF Inhibitors for NSCLC Product and Solutions Table 29. Reliance Lifesciences Targeted Drug VEGF Inhibitors for NSCLC Revenue (USD Million), Gross Margin and Market Share (2019-2021) Table 30. Beaconpharma Corporate Information, Head Office, and Major Competitors Table 31. Beaconpharma Major Business Table 32. Beaconpharma Targeted Drug VEGF Inhibitors for NSCLC Product and Solutions Table 33. Beaconpharma Targeted Drug VEGF Inhibitors for NSCLC Revenue (USD Million), Gross Margin and Market Share (2019-2021) Table 34. Celgene Corporation Corporate Information, Head Office, and Major Competitors Table 35. Celgene Corporation Major Business Table 36. Celgene Corporation Targeted Drug VEGF Inhibitors for NSCLC Product and Solutions Table 37. Celgene Corporation Targeted Drug VEGF Inhibitors for NSCLC Revenue (USD Million), Gross Margin and Market Share (2019-2021) Table 38. Fujifilm Kyowa Kirin Biologics Corporate Information, Head Office, and Major Competitors Table 39. Fujifilm Kyowa Kirin Biologics Major Business Table 40. Fujifilm Kyowa Kirin Biologics Targeted Drug VEGF Inhibitors for NSCLC Product and Solutions Table 41. Fujifilm Kyowa Kirin Biologics Targeted Drug VEGF Inhibitors for NSCLC Revenue (USD Million), Gross Margin and Market Share (2019-2021) Table 42. Hetero Drugs Corporate Information, Head Office, and Major Competitors Table 43. Hetero Drugs Major Business Table 44. Hetero Drugs Targeted Drug VEGF Inhibitors for NSCLC Product and Solutions Table 45. Hetero Drugs Targeted Drug VEGF Inhibitors for NSCLC Revenue (USD Million), Gross Margin and Market Share (2019-2021) Table 46. Global Targeted Drug VEGF Inhibitors for NSCLC Revenue (USD Million) by Players (2019-2021) Table 47. Global Targeted Drug VEGF Inhibitors for NSCLC Revenue Share by Players (2019-2021) Table 48. Breakdown of Targeted Drug VEGF Inhibitors for NSCLC by Company Type (Tier 1, Tier 2 and Tier 3) Table 49. Targeted Drug VEGF Inhibitors for NSCLC Players Head Office, Products and Services Provided Table 50. Targeted Drug VEGF Inhibitors for NSCLC Mergers & Acquisitions in the Past Five Years Table 51. Targeted Drug VEGF Inhibitors for NSCLC New Entrants and Expansion Plans Table 52. Global Targeted Drug VEGF Inhibitors for NSCLC Revenue (USD Million) by Type (2016-2021) Table 53. Global Targeted Drug VEGF Inhibitors for NSCLC Revenue Share by Type (2016-2021) Table 54. Global Targeted Drug VEGF Inhibitors for NSCLC Revenue Forecast by Type (2021-2026) Table 55. Global Targeted Drug VEGF Inhibitors for NSCLC Revenue by Application (2016-2021) Table 56. Global Targeted Drug VEGF Inhibitors for NSCLC Revenue Forecast by Application (2021-2026) Table 57. North America Targeted Drug VEGF Inhibitors for NSCLC Revenue by Type (2016-2021) & (USD Million) Table 58. North America Targeted Drug VEGF Inhibitors for NSCLC Revenue by Type (2021-2026) & (USD Million) Table 59. North America Targeted Drug VEGF Inhibitors for NSCLC Revenue by Application (2016-2021) & (USD Million) Table 60. North America Targeted Drug VEGF Inhibitors for NSCLC Revenue by Application (2021-2026) & (USD Million) Table 61. North America Targeted Drug VEGF Inhibitors for NSCLC Revenue by Country (2016-2021) & (USD Million) Table 62. North America Targeted Drug VEGF Inhibitors for NSCLC Revenue by Country (2021-2026) & (USD Million) Table 63. Europe Targeted Drug VEGF Inhibitors for NSCLC Revenue by Type (2016-2021) & (USD Million) Table 64. Europe Targeted Drug VEGF Inhibitors for NSCLC Revenue by Type (2021-2026) & (USD Million) Table 65. Europe Targeted Drug VEGF Inhibitors for NSCLC Revenue by Application (2016-2021) & (USD Million) Table 66. Europe Targeted Drug VEGF Inhibitors for NSCLC Revenue by Application (2021-2026) & (USD Million) Table 67. Europe Targeted Drug VEGF Inhibitors for NSCLC Revenue by Country (2016-2021) & (USD Million) Table 68. Europe Targeted Drug VEGF Inhibitors for NSCLC Revenue by Country (2021-2026) & (USD Million) Table 69. Asia-Pacific Targeted Drug VEGF Inhibitors for NSCLC Revenue by Type (2016-2021) & (USD Million) Table 70. Asia-Pacific Targeted Drug VEGF Inhibitors for NSCLC Revenue by Type (2021-2026) & (USD Million) Table 71. Asia-Pacific Targeted Drug VEGF Inhibitors for NSCLC Revenue by Application (2016-2021) & (USD Million) Table 72. Asia-Pacific Targeted Drug VEGF Inhibitors for NSCLC Revenue by Application (2021-2026) & (USD Million) Table 73. Asia-Pacific Targeted Drug VEGF Inhibitors for NSCLC Revenue by Region (2016-2021) & (USD Million) Table 74. Asia-Pacific Targeted Drug VEGF Inhibitors for NSCLC Revenue by Region (2021-2026) & (USD Million) Table 75. South America Targeted Drug VEGF Inhibitors for NSCLC Revenue by Type (2016-2021) & (USD Million) Table 76. South America Targeted Drug VEGF Inhibitors for NSCLC Revenue by Type (2021-2026) & (USD Million) Table 77. South America Targeted Drug VEGF Inhibitors for NSCLC Revenue by Application (2016-2021) & (USD Million) Table 78. South America Targeted Drug VEGF Inhibitors for NSCLC Revenue by Application (2021-2026) & (USD Million) Table 79. South America Targeted Drug VEGF Inhibitors for NSCLC Revenue by Country (2016-2021) & (USD Million) Table 80. South America Targeted Drug VEGF Inhibitors for NSCLC Revenue by Country (2021-2026) & (USD Million) Table 81. Middle East & Africa Targeted Drug VEGF Inhibitors for NSCLC Revenue by Type (2016-2021) & (USD Million) Table 82. Middle East & Africa Targeted Drug VEGF Inhibitors for NSCLC Revenue by Type (2021-2026) & (USD Million) Table 83. Middle East & Africa Targeted Drug VEGF Inhibitors for NSCLC Revenue by Application (2016-2021) & (USD Million) Table 84. Middle East & Africa Targeted Drug VEGF Inhibitors for NSCLC Revenue by Application (2021-2026) & (USD Million) Table 85. Middle East & Africa Targeted Drug VEGF Inhibitors for NSCLC Revenue by Country (2016-2021) & (USD Million) Table 86. Middle East & Africa Targeted Drug VEGF Inhibitors for NSCLC Revenue by Country (2021-2026) & (USD Million) List of Figures Figure 1. Targeted Drug VEGF Inhibitors for NSCLC Picture Figure 2. Global Targeted Drug VEGF Inhibitors for NSCLC Revenue Market Share by Type in 2020 Figure 3. Bevacizumab Figure 4. Other Figure 5. Targeted Drug VEGF Inhibitors for NSCLC Revenue Market Share by Application in 2020 Figure 6. Squamous Cell Carcinoma of NSCLC Picture Figure 7. Adenocarcinoma of NSCLC Picture Figure 8. Large Cell Carcinoma of NSCLC Picture Figure 9. Global Targeted Drug VEGF Inhibitors for NSCLC Revenue, (USD Million): 2020 VS 2021 VS 2026 Figure 10. Global Targeted Drug VEGF Inhibitors for NSCLC Revenue and Forecast (2016-2026) & (USD Million) Figure 11. Global Targeted Drug VEGF Inhibitors for NSCLC Revenue Market Share by Region (2016-2026) Figure 12. Global Targeted Drug VEGF Inhibitors for NSCLC Revenue Market Share by Region in 2020 Figure 13. North America Targeted Drug VEGF Inhibitors for NSCLC Revenue (USD Million) and Growth Rate (2016-2026) Figure 14. Europe Targeted Drug VEGF Inhibitors for NSCLC Revenue (USD Million) and Growth Rate (2016-2026) Figure 15. Asia-Pacific Targeted Drug VEGF Inhibitors for NSCLC Revenue (USD Million) and Growth Rate (2016-2026) Figure 16. South America Targeted Drug VEGF Inhibitors for NSCLC Revenue (USD Million) and Growth Rate (2016-2026) Figure 17. Middle East and Africa Targeted Drug VEGF Inhibitors for NSCLC Revenue (USD Million) and Growth Rate (2016-2026) Figure 18. Targeted Drug VEGF Inhibitors for NSCLC Market Drivers Figure 19. Targeted Drug VEGF Inhibitors for NSCLC Market Restraints Figure 20. Targeted Drug VEGF Inhibitors for NSCLC Market Trends Figure 21. Roche Recent Developments and Future Plans Figure 22. Pfizer Recent Developments and Future Plans Figure 23. Allergan Recent Developments and Future Plans Figure 24. Amgen Recent Developments and Future Plans Figure 25. Biocon Recent Developments and Future Plans Figure 26. Reliance Lifesciences Recent Developments and Future Plans Figure 27. Beaconpharma Recent Developments and Future Plans Figure 28. Celgene Corporation Recent Developments and Future Plans Figure 29. Fujifilm Kyowa Kirin Biologics Recent Developments and Future Plans Figure 30. Hetero Drugs Recent Developments and Future Plans Figure 31. Global Targeted Drug VEGF Inhibitors for NSCLC Revenue Share by Players in 2020 Figure 32. Targeted Drug VEGF Inhibitors for NSCLC Market Share by Company Type (Tier 1, Tier 2 and Tier 3) Figure 33. Global Top 3 Players Targeted Drug VEGF Inhibitors for NSCLC Revenue Market Share in 2020 Figure 34. Global Top 10 Players Targeted Drug VEGF Inhibitors for NSCLC Revenue Market Share in 2020 Figure 35. Key Players Market Share Trend (Top 3 Market Share: 2019 VS 2020 VS 2021) Figure 36. Global Targeted Drug VEGF Inhibitors for NSCLC Revenue Share by Type in 2020 Figure 37. Global Targeted Drug VEGF Inhibitors for NSCLC Market Share Forecast by Type (2021-2026) Figure 38. Global Targeted Drug VEGF Inhibitors for NSCLC Revenue Share by Application in 2020 Figure 39. Global Targeted Drug VEGF Inhibitors for NSCLC Market Share Forecast by Application (2021-2026) Figure 40. North America Targeted Drug VEGF Inhibitors for NSCLC Sales Market Share by Type (2016-2026) Figure 41. North America Targeted Drug VEGF Inhibitors for NSCLC Sales Market Share by Application (2016-2026) Figure 42. North America Targeted Drug VEGF Inhibitors for NSCLC Revenue Market Share by Country (2016-2026) Figure 43. United States Targeted Drug VEGF Inhibitors for NSCLC Revenue and Growth Rate (2016-2026) & (USD Million) Figure 44. Canada Targeted Drug VEGF Inhibitors for NSCLC Revenue and Growth Rate (2016-2026) & (USD Million) Figure 45. Mexico Targeted Drug VEGF Inhibitors for NSCLC Revenue and Growth Rate (2016-2026) & (USD Million) Figure 46. Europe Targeted Drug VEGF Inhibitors for NSCLC Sales Market Share by Type (2016-2026) Figure 47. Europe Targeted Drug VEGF Inhibitors for NSCLC Sales Market Share by Application (2016-2026) Figure 48. Europe Targeted Drug VEGF Inhibitors for NSCLC Revenue Market Share by Country (2016-2026) Figure 49. Germany Targeted Drug VEGF Inhibitors for NSCLC Revenue and Growth Rate (2016-2026) & (USD Million) Figure 50. France Targeted Drug VEGF Inhibitors for NSCLC Revenue and Growth Rate (2016-2026) & (USD Million) Figure 51. United Kingdom Targeted Drug VEGF Inhibitors for NSCLC Revenue and Growth Rate (2016-2026) & (USD Million) Figure 52. Russia Targeted Drug VEGF Inhibitors for NSCLC Revenue and Growth Rate (2016-2026) & (USD Million) Figure 53. Italy Targeted Drug VEGF Inhibitors for NSCLC Revenue and Growth Rate (2016-2026) & (USD Million) Figure 54. Asia-Pacific Targeted Drug VEGF Inhibitors for NSCLC Sales Market Share by Type (2016-2026) Figure 55. Asia-Pacific Targeted Drug VEGF Inhibitors for NSCLC Sales Market Share by Application (2016-2026) Figure 56. Asia-Pacific Targeted Drug VEGF Inhibitors for NSCLC Revenue Market Share by Region (2016-2026) Figure 57. China Targeted Drug VEGF Inhibitors for NSCLC Revenue and Growth Rate (2016-2026) & (USD Million) Figure 58. Japan Targeted Drug VEGF Inhibitors for NSCLC Revenue and Growth Rate (2016-2026) & (USD Million) Figure 59. South Korea Targeted Drug VEGF Inhibitors for NSCLC Revenue and Growth Rate (2016-2026) & (USD Million) Figure 60. India Targeted Drug VEGF Inhibitors for NSCLC Revenue and Growth Rate (2016-2026) & (USD Million) Figure 61. Southeast Asia Targeted Drug VEGF Inhibitors for NSCLC Revenue and Growth Rate (2016-2026) & (USD Million) Figure 62. Australia Targeted Drug VEGF Inhibitors for NSCLC Revenue and Growth Rate (2016-2026) & (USD Million) Figure 63. South America Targeted Drug VEGF Inhibitors for NSCLC Sales Market Share by Type (2016-2026) Figure 64. South America Targeted Drug VEGF Inhibitors for NSCLC Sales Market Share by Application (2016-2026) Figure 65. South America Targeted Drug VEGF Inhibitors for NSCLC Revenue Market Share by Country (2016-2026) Figure 66. Brazil Targeted Drug VEGF Inhibitors for NSCLC Revenue and Growth Rate (2016-2026) & (USD Million) Figure 67. Argentina Targeted Drug VEGF Inhibitors for NSCLC Revenue and Growth Rate (2016-2026) & (USD Million) Figure 68. Middle East and Africa Targeted Drug VEGF Inhibitors for NSCLC Sales Market Share by Type (2016-2026) Figure 69. Middle East and Africa Targeted Drug VEGF Inhibitors for NSCLC Sales Market Share by Application (2016-2026) Figure 70. Middle East and Africa Targeted Drug VEGF Inhibitors for NSCLC Revenue Market Share by Country (2016-2026) Figure 71. Turkey Targeted Drug VEGF Inhibitors for NSCLC Revenue and Growth Rate (2016-2026) & (USD Million) Figure 72. Saudi Arabia Targeted Drug VEGF Inhibitors for NSCLC Revenue and Growth Rate (2016-2026) & (USD Million) Figure 73. UAE Targeted Drug VEGF Inhibitors for NSCLC Revenue and Growth Rate (2016-2026) & (USD Million) Figure 74. Methodology Figure 75. Research Process and Data Source

Roche Pfizer Allergan Amgen Biocon Reliance Lifesciences Beaconpharma Celgene Corporation Fujifilm Kyowa Kirin Biologics Hetero Drugs